Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCIB1 + iSCIB1+
- Development stage
- Unknown
- Lead developer
- Scancell Holdings
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**SCIB1 + iSCIB1+** refers to investigational DNA vaccines developed by Scancell for advanced melanoma, evaluated in combination with checkpoint inhibitors like nivolumab + ipilimumab or pembrolizumab. SCIB1 incorporates CD4 and CD8 epitopes from melanoma antigens TRP-2 and gp100 within an antibody framework to target activated dendritic cells, stimulating immune responses against cancer cells. iSCIB1+ is a second-generation version with additional epitopes and improved Fc targeting for broader patient benefit. Administered via needle-free injection up to 11 times over 85 weeks, these vaccines show promising safety, high response rates (up to 85% in early data), improved progression-free survival, and immune activation without added toxicity in phase 2 SCOPE trial (NCT04079166).[1][3][9]
- Brand names
- ImmunoBody
- Other names
- SCIB1/iSCIB1+
02
Targets
PMEL (Melanocyte Protein PMEL)TYRP2 (Tyrosinase-related Protein 2)
Beyond the preview
Go deeper on SCIB1 + iSCIB1+.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCIB1 + iSCIB1+.